Urinary Soluble CD163 Levels Predict IgA Nephropathy Remission Status

Noninvasive biomarkers of disease activity are needed to predict disease remission status in patients with IgA nephropathy (IgAN). Soluble CD163 (sCD163), shed by monocytes and macrophages, is a potential biomarker in diseases associated with excessive macrophage activation. We investigated the asso...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2021-12, Vol.12, p.769802-769802
Main Authors: Gong, Shaomin, Jin, Shi, Li, Yang, Jiang, Wuhua, Zhang, Zhen, Shen, Ziyan, Wang, Jialin, Zhou, Huili, Liu, Xiao, Xu, Xialian, Ding, Xiaoqiang, Shi, Yiqin, Liu, Hong
Format: Article
Language:English
Subjects:
Adult
Antigens, CD - urine
Antigens, Differentiation, Myelomonocytic - urine
biomarker
Biomarkers - urine
Female
Glomerulonephritis, IGA - diagnosis
Glomerulonephritis, IGA - urine
Humans
IgA nephropathy
Immunology
Kidney - pathology
macrophages
Macrophages - metabolism
Macrophages - pathology
Male
Middle Aged
Predictive Value of Tests
Prognosis
Receptors, Cell Surface
remission status
Remission, Spontaneous
Retrospective Studies
Severity of Illness Index
Solubility
urinary soluble CD163
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Noninvasive biomarkers of disease activity are needed to predict disease remission status in patients with IgA nephropathy (IgAN). Soluble CD163 (sCD163), shed by monocytes and macrophages, is a potential biomarker in diseases associated with excessive macrophage activation. We investigated the association of urinary sCD163 (u-sCD163) with histopathological activity and clinical manifestations in 349 patients with biopsy-diagnosed IgAN. U-sCD163 was measured enzyme-linked immunosorbent assay. In patients with IgAN, higher u-sCD163 levels were associated with histological lesions of greater severity, as well as more proteinuria and poorer renal function. Additionally, u-sCD163 was correlated with infiltration of tubulointerstitial CD163 macrophages. High u-sCD163 levels (>3.57 ng/mg Cr) were associated with a 2.66-fold greater risk for IgAN remission failure in adjusted analyses. Adding u-sCD163 levels to the model containing clinical data at biopsy and MEST-C score significantly improved the risk prediction of IgAN remission status (AUC 0.788). Together, our results suggest that u-sCD163 may be a useful noninvasive biomarker to evaluate disease severity and remission status of IgAN.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.769802